NCT07374120Completed
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Community Oncology Setting
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1480 (actual)
- First submitted
- 20 Jan 2026
- Start date
- 1 Feb 2024
- Primary completion date
- 21 Jan 2025
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Chronic myeloid leukaemia
- NCT number
- NCT07374120
What you commit to
- Study type: Observational
- Participants enrolled: 1480
- From 1 Feb 2024 to the primary completion date, 21 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received any systemic treatment indicated for another primary cancer during the study observation period.
Other
- Patients enrolled in interventional clinical trials during the study observation period.
Who the study is looking for
- Patients whose data were accessible for research purposes during the study observation period.
- Patients diagnosed with CML-CP at first recorded diagnosis of CML.
- Patients ≥ 18 years of age at first recorded diagnosis of CML.
- Patients who initiated qualifying 1L therapy for CML-CP during the study identification period. Qualifying 1L therapy treatments consisted of imatinib, dasatinib, bosutinib, or nilotinib as monotherapy.
- Patients with ≥1 visit within The US Oncology Network practices following initiation of 1L therapy and through the end of the study observation period.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.